Literature DB >> 19372988

Host genetic determinants of HIV pathogenesis: an immunologic perspective.

Peter W Hunt1, Mary Carrington.   

Abstract

PURPOSE OF REVIEW: The purpose of this review is to highlight recent advances in our understanding of host genetic determinants of HIV pathogenesis and to provide a theoretical framework for interpreting these studies in the context of our evolving understanding of HIV immunopathogenesis. RECENT
FINDINGS: The first genome-wide association analysis of host determinants of HIV pathogenesis and other recent studies evaluating the interaction between killer cell immunoglobulin-like receptors and human leukocyte antigen alleles have implicated both adaptive and innate immune responses in the control of HIV replication. Furthermore, genetic variation associated with the expression of CCR5 and its ligand have been strongly associated with both decreased susceptibility to HIV infection and delayed clinical progression, independent of their effects on viral replication, suggesting a potential role for CCR5 inhibitors as immune-based therapies in HIV disease.
SUMMARY: Host factors associated with the control of HIV replication may help identify important targets for vaccine design, while those associated with delayed clinical progression provide targets for future immune-based therapies against HIV infection.

Entities:  

Year:  2008        PMID: 19372988      PMCID: PMC3475200          DOI: 10.1097/COH.0b013e3282fbaa92

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  56 in total

1.  Potential underestimation of HLA-C-restricted cytotoxic T-lymphocyte responses.

Authors:  P J Goulder; M Bunce; G Luzzi; R E Phillips; A J McMichael
Journal:  AIDS       Date:  1997-12       Impact factor: 4.177

2.  Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.

Authors:  J W Mellors; A Muñoz; J V Giorgi; J B Margolick; C J Tassoni; P Gupta; L A Kingsley; J A Todd; A J Saah; R Detels; J P Phair; C R Rinaldo
Journal:  Ann Intern Med       Date:  1997-06-15       Impact factor: 25.391

3.  Early protective effect of CCR-5 delta 32 heterozygosity on HIV-1 disease progression: relationship with viral load. The SEROCO Study Group.

Authors:  L Meyer; M Magierowska; J B Hubert; C Rouzioux; C Deveau; F Sanson; P Debre; J F Delfraissy; I Theodorou
Journal:  AIDS       Date:  1997-09       Impact factor: 4.177

4.  Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals.

Authors:  J Eugen-Olsen; A K Iversen; P Garred; U Koppelhus; C Pedersen; T L Benfield; A M Sorensen; T Katzenstein; E Dickmeiss; J Gerstoft; P Skinhøj; A Svejgaard; J O Nielsen; B Hofmann
Journal:  AIDS       Date:  1997-03       Impact factor: 4.177

5.  Association between CCR5 genotype and the clinical course of HIV-1 infection.

Authors:  A M de Roda Husman; M Koot; M Cornelissen; I P Keet; M Brouwer; S M Broersen; M Bakker; M T Roos; M Prins; F de Wolf; R A Coutinho; F Miedema; J Goudsmit; H Schuitemaker
Journal:  Ann Intern Med       Date:  1997-11-15       Impact factor: 25.391

6.  The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression.

Authors:  N L Michael; L G Louie; A L Rohrbaugh; K A Schultz; D E Dayhoff; C E Wang; H W Sheppard
Journal:  Nat Med       Date:  1997-10       Impact factor: 53.440

7.  CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms.

Authors:  Matthew J Dolan; Hemant Kulkarni; Jose F Camargo; Weijing He; Alison Smith; Juan-Manuel Anaya; Toshiyuki Miura; Frederick M Hecht; Manju Mamtani; Florencia Pereyra; Vincent Marconi; Andrea Mangano; Luisa Sen; Rosa Bologna; Robert A Clark; Stephanie A Anderson; Judith Delmar; Robert J O'Connell; Andrew Lloyd; Jeffrey Martin; Seema S Ahuja; Brian K Agan; Bruce D Walker; Steven G Deeks; Sunil K Ahuja
Journal:  Nat Immunol       Date:  2007-10-21       Impact factor: 25.606

8.  Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study.

Authors:  M Dean; M Carrington; C Winkler; G A Huttley; M W Smith; R Allikmets; J J Goedert; S P Buchbinder; E Vittinghoff; E Gomperts; S Donfield; D Vlahov; R Kaslow; A Saah; C Rinaldo; R Detels; S J O'Brien
Journal:  Science       Date:  1996-09-27       Impact factor: 47.728

9.  Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression.

Authors:  S Mummidi; S S Ahuja; E Gonzalez; S A Anderson; E N Santiago; K T Stephan; F E Craig; P O'Connell; V Tryon; R A Clark; M J Dolan; S K Ahuja
Journal:  Nat Med       Date:  1998-07       Impact factor: 53.440

10.  Signal transduction due to HIV-1 envelope interactions with chemokine receptors CXCR4 or CCR5.

Authors:  C B Davis; I Dikic; D Unutmaz; C M Hill; J Arthos; M A Siani; D A Thompson; J Schlessinger; D R Littman
Journal:  J Exp Med       Date:  1997-11-17       Impact factor: 14.307

View more
  9 in total

Review 1.  Mendelian randomization: potential use of genetics to enable causal inferences regarding HIV-associated biomarkers and outcomes.

Authors:  Weijing He; John Castiblanco; Elizabeth A Walter; Jason F Okulicz; Sunil K Ahuja
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

2.  Double-edged genetic swords and immunity: lesson from CCR5 and beyond.

Authors:  Sunil K Ahuja; Weijing He
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

3.  HIV ENV glycoprotein-mediated bystander apoptosis depends on expression of the CCR5 co-receptor at the cell surface and ENV fusogenic activity.

Authors:  Anjali Joshi; Alice M Nyakeriga; Revathi Ravi; Himanshu Garg
Journal:  J Biol Chem       Date:  2011-08-22       Impact factor: 5.157

Review 4.  Vaccine design for CD8 T lymphocyte responses.

Authors:  Richard A Koup; Daniel C Douek
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

5.  Reduced eIF3d accelerates HIV disease progression by attenuating CD8+ T cell function.

Authors:  Ying Pan; Zi-Ning Zhang; Lin-Bo Yin; Ya-Jing Fu; Yong-Jun Jiang; Hong Shang
Journal:  J Transl Med       Date:  2019-05-22       Impact factor: 5.531

6.  CCL3L1-CCR5 genotype improves the assessment of AIDS Risk in HIV-1-infected individuals.

Authors:  Hemant Kulkarni; Brian K Agan; Vincent C Marconi; Robert J O'Connell; Jose F Camargo; Weijing He; Judith Delmar; Kenneth R Phelps; George Crawford; Robert A Clark; Matthew J Dolan; Sunil K Ahuja
Journal:  PLoS One       Date:  2008-09-08       Impact factor: 3.240

7.  HIV-1 disease-influencing effects associated with ZNRD1, HCP5 and HLA-C alleles are attributable mainly to either HLA-A10 or HLA-B*57 alleles.

Authors:  Gabriel Catano; Hemant Kulkarni; Weijing He; Vincent C Marconi; Brian K Agan; Michael Landrum; Stephanie Anderson; Judith Delmar; Vanessa Telles; Li Song; John Castiblanco; Robert A Clark; Matthew J Dolan; Sunil K Ahuja
Journal:  PLoS One       Date:  2008-11-04       Impact factor: 3.240

8.  Role of CCL3L1-CCR5 genotypes in the epidemic spread of HIV-1 and evaluation of vaccine efficacy.

Authors:  Hemant Kulkarni; Vincent C Marconi; Brian K Agan; Carole McArthur; George Crawford; Robert A Clark; Matthew J Dolan; Sunil K Ahuja
Journal:  PLoS One       Date:  2008-11-07       Impact factor: 3.240

9.  Naïve/Effector CD4 T cell ratio as a useful predictive marker of immune reconstitution in late presenter HIV patients: A multicenter study.

Authors:  Veronica Bordoni; Bruno Brando; Pierluca Piselli; Olindo Forini; Federico Enrico Perna; Umberto Atripaldi; Sara Carputo; Federica Garziano; Elisabetta Trento; Giovanna D'Agosto; Alessandra Latini; Manuela Colafigli; Antonio Cristaudo; Alessandra Sacchi; Massimo Andreoni; Gabriella De Carli; Nicoletta Orchi; Sandro Grelli; Arianna Gatti; Carlotta Cerva; Antonella Minutolo; Marina Potestà; Maria Luisa Di Martino; Francesco Ortu; Paola Selva; Laura Del Pup; Irene Guarnori; Patrizia Lorenzini; Giusy Capuano; Andrea Antinori; Chiara Agrati
Journal:  PLoS One       Date:  2019-12-23       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.